Business
Ventripoint Updates Submission to U.S. Food and Drug Administration for its Next Generation, AI-powered Heart-scanning Technology
(TheNewswire) Updates to submission of VMS+ 4.0 provided to FDA on January 17, 2025 ...
About this update from Ventripoint Diagnostics Ltd.
[{"type":"text","content":"Ventripoint Updates Submission to U.S. Food and Drug Administration for its Next Generation, AI-powered Heart-scanning Technology \n\n\n (TheNewswire)\n \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n Updates to submission of VMS+ 4.0\nprovided to FDA on January 17, 2025\n \n\n\n\n\n\n Ventripoint will market new advances\nin USA after FDA clearance\n \n\n\n\n\n\n Toronto, Ontario –\n \n\n TheNewswire -\n \n\n January 21, 2025\n \n\n -\nVentripoint Diagnostics Ltd.\n \n\n (\"\n \n\n Ventripoint\n \n\n \" or\nthe \"\n \n\n Company\n \n\n \"), (TSXV:VPT; OTC:VPTDF)\n \n\n has\nreached another development milestone by updating the submission of\nits next generation of software, VMS+ 4.0, to the U.S. Food and Drug\nAdministration\n \n\n (“FDA”)\n \n\n for clearance.  The update addresses questions\nregarding cybersecurity and AI.\n \n\n\n\n This latest advancement of Ventripoint’s proprietary\ntechnology, VMS+ 4.0, delivers two significant enhancements to improve\nclinical workflows\n \n\n\n\n\n\n AI-assisted echocardiogram image analysis\n \n\n\n\n\n\n Simplified sensors pairing workflow.\n \n\n\n\n\n\n These new improvements are in addition to the benefits\nof VMS+ 3.0\n \n\n\n\n\n\n Full-scope use so all patient groups can be easily\nscanned and assessed.\n \n\n\n\n\n\n Magnet-free sensors increasing the scope of patients\nwho can benefit\n \n\n\n\n\n\n Vendor-neutral interfacing with any ultrasound\nmachine.\n \n\n\n\n\n\n “Ventripoint is a pioneer in the application of AI to\nechocardiography and VMS+ 4.0 is the result of over two years of\nresearch and development,” said Ventripoint President and CEO, Hugh\nMacNaught. “We are grateful for the collaboration by the Avania team\nto support this update to our submission. Upon FDA clearance we look\nforward to offering U.S. hospitals one of the simplest, most\neffective, non-invasive heart-imaging tools available.”\n \n\n\n\n “Avania is proud to support Ventripoint on this\nimportant innovation. As a long-term partner, we have been continually\nimpressed with Ventripoint's progress and the continual improvements\nthey have made to their products,” said Joel Ironstone, VP,\nRegulatory & Advisory Services for Avania. “We excitedly look\nforward to working with ...